Roche's Genentech is sticking with Orionis Biosciences, handing over $105 million upfront as part of its second deal with the ...

The ODAC cited concerns with patient populations in clinical trials used to support the proposed expansion. Johnson & Johnson ...

Orionis Biosciences, a privately held company, announced a second multi-year collaboration with Genentech, a member of the ...

Roche, along with Bristol Myers Squibb, Novo Nordisk, AbbVie, Eli Lilly and others, is making inroads into molecular glues to ...

Orionis Biosciences Inc. is sticking with Genentech Inc. in a second deal to discover small-molecule monovalent glue therapies for treating cancer. Privately held Orionis is getting $105 million up ...

Genentech, a Roche Group company (OTCQX:RHHBY) (OTCQX:RHHBF), said on Tuesday that a U.S. FDA advisory committee voted ...

Genentech, considered one of the biotech industry’s founding companies, plans to build a $700 million, 700,000-square-foot ...

The biotech giant's new facility is part of a larger U.S. investment strategy, though it may roll back its buildout if the ...

HOLLY SPRINGS, N.C. -- Genentech, a leading biotechnology company based in San Francisco, is set to build a $700 million ...

Genentech plans to invest $700 million in a new facility in Holly Springs, North Carolina, creating 420 jobs and joining the ...

Commerce officials approved an incentives package worth up to $13.1 million for the company, which plans to build a $700 ...

A new promo for Roche’s blockbuster hemophilia A drug Hemlibra focuses less on those with the genetic bleeding disorder and ...